Healthcare

Addiction Biotech Cannabis Genetics Healthcare Medical Devices Pharmaceutical Science Veterinary
News Release Digital Asset Direct

Can This Company’s Birth Control Patch Disrupt The Contraceptive Market?

Agile Therapeutics, Inc.

From Evofem Biosciences Inc. ’s (OTCMKTS: EVFM) Phexxi vaginal gel contraceptive to Dare Bioscience Inc. ’s (NASDAQ: DARE) Ovaprene, an investigational hormone-free monthly intravaginal contraceptive, the market is never in short supply of birth control products. While the issue of birth control and abortion can be embroiled in continuous debates and controversies, contraceptives have been known to reduce the rate of unintended pregnancies, the need for unsafe abortions, and HIV transmissions from mothers to newborns. The need is strong - a 2020 report by the World Health Organization (WHO) said that among 1.9 billion reproductive-age women (15 to 49 years) globally in 2019, around 1.1 billion women require family planning and 270 million of those have an unmet need for contraception. Disruptive Contraceptive Patch? The rising number of women with unmet contraceptive drugs and device needs could present unique opportunities for industry players. Agile Therapeutics Inc. ’s (NASDAQ: AGRX) Twirla® (levonorgestrel and ethinyl estradiol) transdermal system could be one innovative product with the potential to disrupt the industry. New Jersey-based Agile Therapeutics is a forward-thinking women’s healthcare company dedicated to fulfilling the unmet needs of today’s women. The company’s product and product candidates are designed to offer women more freedom and flexibility through additional contraceptive options. Agile Therapeutics Chairman and CEO Al Altomari, speaking at the H.C. Wainwright 24th Annual Global Investment Conference in September, revealed that the company is currently focused on the growth of its first Food and Drug Administration (FDA)-approved product Twirla®. Twirla®, the company reports, is the first and only birth control patch delivering a low dose of estrogen. Twirla delivers 30 micrograms (mcg) of estrogen daily, the lowest exposure of estrogen in a transdermal contraceptive option. Unlike most oral contraceptives on the market that women take at least 21 days each month, Twirla® uses just three patches a month. Agile Therapeutics plans to commercialize and upscale Twirla through its business plan — non-retail channel growth driver ( Afaxys GPO ) and retail channel growth drivers (telemedicine providers like Nurx & Twirla’s DTC CTV commercial ). With the growth of Twirla® being the main focus, the company believes that building a U.S. women’s health franchise on the foundation of the patch’s commercial success can enhance value for shareholders. “We have sought out and will continue to explore partnerships and opportunities that leverage our existing infrastructure, including co-promotion and business development opportunities,” Altomari said. Cash On Hand And The Way Forward Agile Therapeutics raised net proceeds of approximately $12.2 million through its at-the-market (ATM) offering in the second quarter of 2022 and $22.2 million in an upsized public offering in July 2022. The company reduced the outstanding principal amount owed to Perceptive Advisors to $3 million with proceeds from ATM. Agile Therapeutics established a new $75 million ATM in August 2022. From the end of the fourth quarter to the end of the second quarter of 2022, the company reduced its quarterly operating expenses (OPEX) from $18.2 million to $11.3 million while still growing Twirla demand by 27%. The company now believes it has sufficient cash on hand to fund operations through the end of 2022. In the second quarter of 2022, Agile Therapeutics realized net product sales revenue of $2.1 million, an increase of 75% compared to the second quarter of 2021 revenue of $1.2 million. Total operating expenses for the second quarter of 2022 were $11.3 million. Non-retail sales primarily associated with the Afaxys partnership are expected to significantly accelerate in the second half of 2022. Non-retail channels experience higher gross-to-net discounting compared to retail channels and therefore the company expects overall gross-to-net discounts to increase as a percentage of gross revenue. Agile Therapeutics intends to use its resources to continue to grow Twirla® and to improve on its performance as it prepares to report third-quarter 2022 financial results and Twirla® growth update in November. One of the Company’s financial goals is to become cash flow positive. “Our focus in 2022 has been on growing Twirla and advancing towards generating positive cash flow,” said Agile Therapeutics Chairman and Chief Executive Officer Al Altomari. “In 2022, we have significantly reduced our operating expenses by redesigning how we work to gain efficiencies and implemented a plan we believe can drive Twirla growth through our Afaxys partnership, connected TV (CTV) campaign, and growing the telemedicine channel. ” Agile Therapeutics is a women's healthcare company dedicated to fulfilling the unmet health needs of today’s women. Our product and product candidates are designed to provide women with contraceptive options that offer freedom from taking a daily pill, without committing to a longer-acting method. Our initial product, Twirla®, (levonorgestrel and ethinyl estradiol), a transdermal system, is a non-daily prescription contraceptive. Twirla is based on our proprietary transdermal patch technology, called Skinfusion®, which is designed to allow drug delivery through the skin. This post contains sponsored advertising content. This content is for informational purposes only and is not intended to be investing advice. Contact Details Matt Riley - Head of Investor Relations & Corporate Communications mriley@agiletherapeutics.com Company Website https://agiletherapeutics.com/

October 26, 2022 08:00 AM Eastern Daylight Time

News Release

Amid A Turbulent Industry, This Cannabis Company Shines Like A Diamond In the Rough

LiveWire Ergogenics, Inc.

The pandemic was a monumental moment for the cannabis industry as marijuana became a household essential. In many states, dispensaries were declared essential businesses and were allowed to remain open, resulting in a 46% increase in legal cannabis sales over 2019 to $17.5 billion in 2020. Entrepreneurs flocked to the scene, and investors readily backed the industry. with large investments, often time via so-called SPACs. However, the past several months have marked a return to pre-pandemic levels. While the cannabis industry is still predicted to expand and grow, the industry is witnessing an adaption curve. Between heavy taxation, cultivators abandoning licenses, and the pressure of growing inflation, many companies have put up “For Sale” signs or are looking at tough times ahead. A Diamond In The Rough? The Party’s Just Getting Started For LiveWire Ergogenics LiveWire Ergogenics, Inc. (OTC: LVVV) (“LiveWire”) is a company that focuses on acquiring and managing special-purpose real estate properties that will serve as bases to help discover and develop high-end organic cannabis specialty products. LiveWire firmly positions itself in the center of the health and wellness industry. The cannabis industry as a whole has seen a recent downturn in profits resulting in missed rent payments and cultivation facilities shutting down. While the industry as a whole is looking at positive growth, the reality on the ground for many cannabis companies may be bleak. Property deals have been falling through more frequently as companies struggle to make ends meet. Companies are facing difficulties with the slowing general economy paired with legislative challenges that plague the cannabis industry. Public policy is an uphill battle. Despite these challenges in the market, LiveWire is prospering. Its Q2 results show solid growth and a positive future. In Q2, LiveWire generated $463,313 in revenue, which was a 323% increase from 2021’s Q2. Net profit also saw considerable growth; the company’s net profit was $183,122 in Q2 compared to a loss of $579,792 during 2021’s Q2. LiveWire believes that U.S. cannabis companies must be well-managed and offer unique and high-quality products via legal and environmentally conscious operations, not low-quality mass production. That is a significant component of their success and the Company believes that diligent and disciplined investors will be presented with an exciting second opportunity to benefit from one of the last decade's fastest-growing markets for any industry. They expect to see reliable growth in cannabis industry sales going forward, and while still in the revenue startup phase that seems to already reflect in their own sales. LiveWire has developed Estrella Ranch as the central hub for all LiveWire and subsidiary operations. This property is being developed into the first “Estate Grown Weedery,” and eventually the ultimate cannabis destination in California. As of October, the Ranch has passed all quarterly inspections by the county and state and was renewed for its annual permit. The Estrella Ranch has also received nine new cultivation permits that will allow for an expanded outdoor cultivation area. As Q3 and Q4 approach, the company is exploring the buildout of an already existing building on Estrella Ranch as an indoor cultivation area. If implemented and considered economical this is expected to help further drive revenue. Based on Livewire’s philosophy that any cannabis company has to be subject to strict financial principles and must operate with low overhead and reasonable debt burden to produce increasing revenues and profits, LiveWire does not seem to be experiencing the same dilemmas that other companies in the industry are facing. If their Q2 report and business expansion plans are any indications, LiveWire seems to have a strong future ahead of it. LiveWire Ergogenics focuses on acquiring, managing, and licensing well-qualified cannabis real estate locations to establish fully compliant and permitted facilities to produce cannabis-based products and establish relationships for the statewide distribution of these products in California. This includes developing and licensing high-quality organic cannabinoid-based products and services and creating the high-quality "Estrella Grown Weedery™" brand via its subsidiary/affiliate companies Estrella Ranch Partners, Estrella River Farms, Makana Ola, and CaliCruz Farms. LiveWire Ergogenics does not produce, sell, or distribute products that violate the United States Controlled Substances Act. This post contains sponsored advertising content. This content is for informational purposes only and is not intended to be investing advice. Contact Details Tristan Cavato ir@livewireergogenics.com

October 26, 2022 08:00 AM Eastern Daylight Time

Cortland Biomedical Announces Capabilities for Creating Textile Structures Incorporating Radiopaque Fibers

Cortland Biomedical

Cortland Biomedical, a full-service medical textiles product development partner that provides access to a full spectrum of global engineering, design and manufacturing capabilities, today announced that it now has capabilities for processing radiopaque fibers. By incorporating radiopaque fibers into diagnostic and interventional medical devices, it allows the devices to become clearly visible under fluoroscopy while maintaining the mechanical properties desired for the specific application. Improved visibility under fluoroscopy and x-rays – including better contrast and sharpness of the image– will allow surgeons to optimally position the device or implant. Furthermore, textile-based implants can also incorporate radiopaque fibers, which will enable surgeons to view the position of the implant under fluoroscopy months or even years after surgical placement. The incorporation of textiles allows for lower profile and more flexible medical devices that can enable less invasive surgical procedures. Cortland Biomedical has an extensive range of knitting, weaving, and braiding capabilities, enabling it to work with its customers to develop complex, customized textile structures with highly tailored mechanical properties. Any of these methods can be applied to processing radiopaque fibers, which are currently available in PET and UHMWPE. “We’re always aiming to break down the barriers of what’s traditionally been possible when it comes to engineering textile structures,” said John Greco, VP Sales, Cortland Biomedical. “We’re pleased to now be able to work with radiopaque fibers, which will give our customers more choice when it comes to material selection and allow them to create devices that can be seen more clearly under fluoroscopy without the need for additional markers.” About Cortland Biomedical Cortland Biomedical custom designs and manufactures high-performance biomedical textile structures leveraging years of experience in medical textile engineering methods including knitting, braiding, and weaving. Its thoughtful design concepts challenge the status quo. Cortland Biomedical’s unique combination of advanced equipment and technology, a seasoned medical textile-specific engineering team, and first-rate R&D capabilities allows it to tackle customers’ complex challenges with the innovation and agility expected in the medical device industry. Learn more at cortlandbiomedical.com. Contact Details SVM Public Relations Jordan Bouclin +1 401-490-9700 Jordan.bouclin@svmpr.com Company Website https://www.cortlandbiomedical.com/

October 25, 2022 10:00 AM Eastern Daylight Time

Hong Kong Baptist University-led research identifies Salvia miltiorrhiza extract as potential preventive agent for gastric cancer induced by bile reflux

Hong Kong Baptist University

HONG KONG SAR - Media OutReach - 25 October 2022 - Research led by the School of Chinese Medicine at Hong Kong Baptist University (HKBU) has identified cryptotanshinone, a compound extracted from the Chinese herbal medicine Salvia miltiorrhiza, with the potential for the treatment and prevention of gastric cancer associated with bile reflux. The researchers unveiled the mechanism of how bile reflux induces gastritis and gastric cancer. They explained that refluxed bile acids (BAs) lead to the proliferation of pro-inflammation bacteria that promote gastric carcinogenesis, the formation of cancer. Professor Jia Wei, Associate Dean (International Collaboration) of Chinese Medicine and Cheung On Tak Endowed Professor in Chinese Medicine at HKBU, has identified cryptotanshinone with the potential for the treatment and prevention of gastric cancer associated with bile reflux. The research findings have been published in the international scientific journal Advanced Science. Role of bile reflux in gastric cancer unclear Bile, secreted by the liver, is stored in the gallbladder and is released to the duodenum to help digest fat. When the pylorus connecting the stomach and the duodenum is damaged or fails to work properly, bile in the duodenum can enter the stomach, causing gastritis. People with stomach surgery complications, peptic ulcers or gallbladder removal surgery have higher risks of bile reflux. However, the mechanism of how bile reflux induces gastric carcinogenesis remains unclear. Professor Jia Wei, Associate Dean (International Collaboration) of Chinese Medicine and Cheung On Tak Endowed Professor in Chinese Medicine at HKBU, in collaboration with researchers from Shanghai Jiao Tong University Affiliated Sixth People’s Hospital, conducted a study on how bile reflux induces gastric carcinogenesis, and looked for new prevention and therapeutic approaches. Professor Jia said: “We unveiled for the first time the underlying mechanism by which bile reflux promoted the development of gastric carcinogenesis. It offers important clinical insights on the development of novel prevention and therapeutic approaches for the disease. Based on the newly discovered mechanism, we identified cryptotanshinone as a potential Chinese medicine-based pharmaceutic agent for the prevention and treatment of gastric carcinogenesis due to bile reflux.” Bile reflux alters gastric environment The research team analysed the gastric juice samples of 50 patients with bile reflux gastritis (BRG group), 50 patients with gastric cancer (GC group) and 45 subjects in the control group using chromatography and mass spectrometry techniques. It was found that the amounts of BAs, the major component of bile, in the gastric juice samples of BRG and GC groups are significantly higher than in the control group. Furthermore, the acidities of gastric juice samples of the BRG group (pH value about 3.5) and the GC group (pH value about 4) are drastically lower than in the control group (pH value about 2). The phenomenon is explained by the fact that BAs are weak acids compared with strong gastric acid, and their influx into the stomach changed the gastric environment by upsetting the normal acid-base balance of the gastric juice. Further investigation found that a specific type of BA, called taurodeoxycholic acid (TDCA), showed a strong positive correlation with pH value of gastric juice samples of the BRG and GC groups. Previous studies showed that bile reflux is closely related to chronic gastric inflammation and gastric carcinogenesis. The researchers thus examined the concentrations of lipopolysaccharide (LPS), a pro-inflammation cytokine, in the gastric juice of the 145 subjects above, and found that the BRG and GC groups have LPS concentrations significantly higher than those of the control group. Change in microbiota associates with gastric carcinogenesis As LPS is produced and found in the outer membrane of certain kinds of bacteria, the researchers applied gene sequencing and other techniques and confirmed that LPS-producing bacteria are significantly more abundant in the gastric juice of BRG and CG groups compared to the control group. Among these LPS-producing bacteria, a species called P. melaninogenica had the highest relative abundance. From these experimental results, it is suggested that bile reflux induces significant changes in the gastric environment, alters the gastric microbiota, and results in the development of gastritis and gastric carcinogenesis. The hypothesis was tested with a series of in vitro and in vivo experiments in mice, which confirmed that application of TDCA and LPS promotes gastric epithelial cell proliferation, and induces gastric inflammation. Cellular and molecular analysis revealed that P. melaninogenica promoted gastric inflammation in mice by activating the IL-6/JAK1/STAT3 pathway, a chain of interactions between proteins in a cell involved in processes such as immunity, cell division, cell death, and tumour formation. Cryptotanshinone as potential pharmaceutic agent After unveiling the mechanism of bile reflux-induced gastric cancer, the researchers turned to explore a corresponding preventive and therapeutic approach. They focused on cryptotanshinone, a bioactive compound isolated from the roots of Salvia miltiorrhiza, which is a Chinese herbal medicine that facilitates blood circulation with an anti-inflammatory effect. Cryptotanshinone is also known as an inhibitor of the STAT3 signaling pathway in cells. The researchers tested the effects of cryptotanshinone with a bile reflux mouse model developed through surgery. In a group of eight mice without application of cryptotanshinone, three mice developed gastric lesions 50 weeks after surgery. However, in another group of six mice injected with cryptotanshinone, no obvious gastric lesions were observed. The results suggested that cryptotanshinone has abolished the effects of TDCA and LPS in activating the IL-6/JAK1/STAT3 pathway. “Based on the research findings, it can be concluded that cryptotanshinone is a potential Chinese medicine-based pharmaceutic agent for the prevention and treatment of gastric carcinogenesis due to bile reflux. It provides an alternative strategy for the development of medication which targets on the newly discovered mechanism of how bile reflux induces gastric carcinogenesis,” said Professor Jia. Contact Details HKBU Communication and Public Relations Office Christina Wu hkbunews@hkbu.edu.hk

October 25, 2022 09:00 AM Eastern Daylight Time

Image

A Growing Body of Research Supports the Positive Impact of Massage Therapy For Mental Health

American Massage Therapy Association

The American Massage Therapy Association (AMTA) is sharing recent research supporting the benefits of massage therapy for stress, anxiety and depression. In a time when the Anxiety and Depression Association of America (ADAA) ranks anxiety as the country’s most common mental illness – and depression as the leading cause of disability for people ages 15 to 44 1, people with mental health issues are turning to a range of wellness strategies, including massage therapy which has a positive impact on the body and mind. During AMTA’s National Massage Therapy Awareness Week®, explore the latest studies on massage therapy for mental health. Studies on Massage for Stress and Anxiety A recent study by German researchers indicated that short-term interventions such as massage therapy can robustly reduce stress on a psychological and physiological level by boosting the body’s principal engine for relaxation – the parasympathetic nervous system. In the study, researchers measured how massage can affect heart rate variability. When the parasympathetic nervous system is active, during rest and relaxation, the heart rate variability is high. The researchers found that just 10 minutes of massage created “significant increases” in heart rate variability. 2 Another 2021 Mayo Clinic study showed positive results on the benefits of massage therapy for anxiety in preoperative surgical patients. After receiving a 15-minute non-therapeutic hand massage, patients experienced lower anxiety levels and increased satisfaction. 3 New Research on Massage Therapy for Chronic Pain and Depression Research also indicates that massage can improve mood and reduce depression in those living with chronic pain. In fact, a scientific journal “Brain Sciences” recently covered a 2020 trial on women with chronic back pain whose depressive symptoms and negative body image were significantly reduced after receiving slow, superficial strokes along the back, neck and dorsal limbs. 4 In addition, a recent Australian pilot study examined the feasibility and acceptability of partner-delivered relaxation massage, and whether massage can reduce symptoms of prenatal anxiety, stress and depression. The results showed that massage therapy was linked to a large reduction in anxiety and depression symptoms and a moderate reduction of stress. Pregnant women who received massage therapy reported a positive benefit from massage of 78 mm (range 29 – 100) on a 100 mm visual analog scale. 5 Massage For Youth Struggling with Mental Health Issues Mental health issues are on the rise for children in the U.S. Many recent studies point to the benefits of using massage in addressing a range of psychological issues in youth, such as attention disorders, aggression, anxiety, depression and post-traumatic stress disorder. In a 2019 study on eating disorders and depression, researchers found that excessively low-dopamine levels were increased following one month of daily 20-minute massages. 6 Another 2019 study compared the effectiveness of soft tissue manipulation and a relaxation technique (Jacobson’s progressive relaxation) in reducing anxiety levels in young adults. The researchers found that the level of perceived anxiety decreased “significantly” in the group receiving soft tissue manipulation. 7 “Research on the efficacy of massage therapy for mental health continues to show great promise,” says Michaele Colizza, AMTA National President. “In fact, more and more consumers are turning to massage therapy as part of an integrative approach to care for improving mental health and well-being.” It’s an Important Moment in Time for Massage for Mental Health Over the last few years, the COVID-19 pandemic has had a marked effect on the country’s mental health. According to the U.S. Census Bureau, more than 42% of people surveyed reported symptoms of anxiety or depression during the pandemic. Researchers are concerned that the increase in mental health issues could linger long after the pandemic has subsided, and many integrative health experts believe that massage therapy can be an important part of the solution in helping alleviate stress, anxiety and depression. 8 About The American Massage Therapy Association The American Massage Therapy Association, the most trusted name in massage therapy, is the largest non-profit, professional association serving massage therapists, massage students and massage schools. The association is directed by volunteer leadership and fosters ongoing, direct member-involvement through its 51 chapters. AMTA works to advance the profession through ethics and standards, the promotion of fair and consistent licensing of massage therapists in all states, and public education on the benefits of massage. To find a qualified massage therapist in your area, please visit AMTA’s Find a Massage Therapist Locator Service ™. Research Citations 1. Anxiety & Depression Association of America (ADAA): Facts & Statistics | Anxiety and Depression Association of America, ADAA 2. University of Konstanz. “Ten minutes of massage or rest will help your body fight stress.” ScienceDaily. September 2020. http://www.sciencedaily.com/releases/2020/09/200918104305.htm. 3. Zghihong, Bauer, Aaberg, Pool, Van Rooy, Schroeder, Finney. “Benefits of hand massage on anxiety in preoperative outpatient: A quasi-experimental study with pre- and post-tests.” https://pubmed.ncbi.nlm.nih.gov/32919894/ 4. Effect of Psycho-Regulatory Massage Therapy on Pain and Depression in Women with Chronic and/ or Somatoform Back Pain: A Randomized Controlled Trial - PubMed (nih.gov) 5. Hall HL, Munk NK, Carr BH, Fogarty SR, Cant RB, Holton SR, Weller CL, Lauche RM. Maternal mental health and partner-delivered massage: A pilot study. Women Birth. 2021 May;34(3):e237-47. 6. Tiffany Field. " Pediatric massage therapy research: A narrative review." Children (Basel) 2019 Jun; 6(6): 78. 7. Wilczynska, Lysak-Radomska, Podczarska-Glowacka, Jolanta Zajt, Dornowski, Skonieczny " Evaluation of the effectiveness of relaxation in lowering the level of anxiety in young adults." Int J Occup Med Environ Health 2019;32(6):817-824. 8. Vahration, Blumberg, Terlizzi, Schiller. “Symptoms of Anxiety or Depressive Disorder and Use of Mental Health Care Among Adults During the COVID-19 Pandemic” – United States, August 2020-February 2021. MMWR Morb Mortal Wkly Rep 2021;70:490-494. https://www.cdc.gov/mmwr/volumes/70/wr/mm7013e2.htm?s_cid=mm7013e2_w Contact Details American Massage Therapy Association Kristin Taylor +1 847-905-1425 communications@amtamassage.org Company Website https://www.amtamassage.org/

October 24, 2022 12:50 PM Eastern Daylight Time

Image

NASDAQ: AGRX Agile Therapeutics Anticipates Increased Growth In Q3 of 2022

Agile Therapeutics, Inc.

Contact Details Matt Riley - Head of Investor Relations & Corporate Communications mriley@agiletherapeutics.com Company Website https://agiletherapeutics.com/

October 21, 2022 11:00 AM Eastern Daylight Time

Video

News Release

Consumers Are Demanding More From Cannabis Companies — Here’s What Some Are Looking For

LiveWire Ergogenics, Inc.

The cannabis industry has undergone drastic changes in recent years, and as marijuana becomes more mainstream, consumers are demanding more from cannabis companies. No longer are the days when consumers will settle for a plastic zip lock bag of questionable quality and purity underground weed — they want choices that reflect their lifestyle and values. Many consumers report that they want a high-quality lifestyle brand and one of the things they are looking for is an organic, hand-cut, pesticide-free, and easy-to-consume cannabis product. Companies that embody these values will be better positioned to become the go-to products for more consumers. Why Do Consumers Want Lifestyle Brands? A growing percentage of consumers care more about the quality and sustainability of the brands they engage with. In a recent survey by Stifel and Morning Consult, more than half of the survey’s respondents shared they had bought from a new brand specifically for its transparent, environmentally responsive, and sustainable practice. When it comes to the cannabis industry, there is a preference for hand-trimmed and hand-grown cannabis. Colloquially known as craft cannabis, companies willing to prioritize hand-trimmed cannabis grown without pesticides and machines will have an easier task of creating high-end products that consumers flock to. Cannabis companies would be wise to look to the lifestyle brand journey of other consumer packaged goods (CPG). Researchers see lots of comparisons between the growth of lifestyle brands in high-end coffee companies and the cannabis industry. Similarly to how high-end coffee consumers are more loyal to brands that boost sustainable heritage, product origins, ethical sourcing, and roasts, a growing number of cannabis consumers are following suit. California is in the process of implementing a product origin program similar to the California wine industry for cannabis. Companies that can leverage a consumer-centric approach to the cannabis industry might find success in the coming years as luxury cannabis becomes more available and accessible to the public. What Companies Are Doing It Right? LiveWire Ergogenics Inc. (OTCMKTS: LVVV) (“LiveWire”) is a company that focuses on acquiring and managing special-purpose real estate properties that qualify for the discovery and development of high-end organic cannabis products. Because of this focus on selecting compliant real estate, LiveWire can hone in on projects that allow for high-end cultivation and set the Company apart from the competition, especially from mass producers of low-quality products. In order to operate economically, LiveWire has developed its Estrella Ranch as the central hub for all LiveWire and subsidiary operations. The Estrella Ranch’s location is ideal for cultivating a high-end organic-style product in a micro-climate that can allow for all-year-round production. Its tractor-less operation is focused on producing high-quality, hand-crafted outdoor products. Additionally, the property’s ultimate goal is to be the world’s first Estate Grown Weedery, an ultimate cannabis destination. This goal aligns well with the Company’s health and wellness lifestyle value. Consumers want an experience from their lifestyle brand of choice, and LiveWire seems to be an example of a company positioning itself well to deliver. The Company focuses on acquiring, managing, and licensing well-qualified cannabis real estate locations to establish fully compliant and permitted facilities to produce cannabis-based products and establish relationships for the statewide distribution of these products in California. This includes developing and licensing high-quality organic cannabinoid-based products and services and creating the high-quality "Estrella Grown Weedery™" brand via its subsidiary/affiliate companies Estrella Ranch Partners, Estrella River Farms, Makana Ola, and CaliCruz Farms. LiveWire Ergogenics does not produce, sell, or distribute products that violate the United States Controlled Substances Act. This post contains sponsored advertising content. This content is for informational purposes only and is not intended to be investing advice. Contact Details Tristan Cavato ir@livewireergogenics.com

October 19, 2022 09:24 AM Eastern Daylight Time

LMCC Returns October 20 & 21 To Hudson Yards: Presenting The World’s Top Cannabis & CBD Beauty, Wellness, Food & Beverage Brands

LMCC Ventures LLC

New York, NY, October 18, 2022 — Luxury Meets Cannabis Conference (LMCC) today announced the complete program for its Fall 2022 Edition, which returns on October 20 & 21 in Hudson Yards, New York City. Launched in 2018 as a first-of-its-kind B2B trade event, LMCC has grown into the go-to resource and venue for product discovery and extensive category education, connecting visionary CBD and Cannabis brands across the beauty/wellness, food/beverage, and technology/lifestyle accessory categories to mainstream retailer buyers, luxe dispensaries, media, and investors. As an indication of the excitement around the emerging New York legal Cannabis market and the official brand showcase mix at LMCC, 100+ A-tier retail outlets – LMCC’s highest rate to date – have registered to attend the show including KITH, Standard Dose, Curaleaf, Bloomingdale’s, Rise Cannabis, Etain, The Vitamin Shoppe, Shen Beauty, and many others. LMCC’s inaugural infused Food & Beverage Hall will also debut, which will feature the finest food/culinary, beverage, consumables, and confectionery brands in the space — especially timely as alcohol sales in the U.S. continue to decline. This Harrods-esque, immersive (and delectable) experience will spotlight leading brands such Cann, Kiva Confections, oHHo, Cycling Frog, Cloud 11, Black Dahlia, L8, Sass, Chef For Higher, and many more. More than 700 business attendees from around the world will explore the LMCC Official Brand Showcase — a pre-vetted, store-ready exhibition — paired with a full schedule of keynote talks, brand presentations, and business networking. For the most up-to-date information on partners, exhibiting brands and speakers, visit lmccshow.com. LMCC FALL 2022 OFFICIAL BRAND SHOWCASE DIRECTORY Astraèa & Co. Black Dahlia CANDOR CANN Chef for Higher Cloud 11 Cycling Frog Daily Habit Drew Martin errbshop Franny’s Farmacy Function Botanicals The Healing Rose Hudson Cannabis Innocan Pharma K’dara Kiva L8 LEUNE LumiBloom MĀSK Skincare oHHo Plantwise REUNION Sackville & Co. SASS StellaVia Stone Road UB Super / Meticulous Skincare WALALA LMCC SPEAKER SCHEDULE NOW LIVE See 50 leading executives on stage from Ulta Beauty, Adweek, New York State Cannabis Control Board, Merida Capital Holdings, Adweek, Different Leaf, NYC Mayor’s Office, Food & Wine, Standard Dose, Women’s Health, and Bon Appétit and many others: View LMCC Fall 2022 Speaker Schedule Here ### Attendee Tickets: Two-day, all-access passes to LMCC 2022 are $695. Purchase passes HERE. Retail Buyer Registration: Admission is complimentary only for qualified retail buyers and their teams. Stores, dispensaries, and e-tailers only can register HERE. Sponsors: LMCC is proud to partner with Merida Capital Holdings Brand Applications: Now Accepting Submission for LMCC May 2023 Brands Can Now Reserve Space for LMCC 2023 Here About LMCC: Founded in 2018, LMCC Ventures LLC is the parent company of the annual Luxury Meets Cannabis* Conference (LMCC) in New York City. LMCC is the premier B2B event connecting A-tier retailers, media, investors, leading dispensaries and CPG executives to premium CBD, hemp and Cannabis brands — with a keen focus on beauty, wellness, food & beverage. Past participants include retailers like Sephora, Nordstrom, Credo Beauty, and Bloomingdale’s; media including The New York Times, Glossy, Travel & Leisure, O, The Oprah Magazine, and Robb Report; and speakers from Mitch Baruchowitz (Merida Capital Holdings) and Cindy Capobianco (Lord Jones) to Bobbi Brown and Frederic Fekkai. For more information on LMCC, visit lmccshow.com. Find LMCC socially on LinkedIn and Instagram. Guidelines & Legal: no smoking or vaping on any kind permitted inside the venue. Local laws strictly apply. Contact Details Katie Shapiro +1 303-882-5596 katie@katieshapiromedia.com Company Website https://www.lmccshow.com/

October 19, 2022 09:00 AM Eastern Daylight Time

Chill Brands kicks off "new era" with website relaunch

Chill Brands Group PLC

Contact Details Proactive Proactive UK Ltd +44 20 7989 0813 uk@proactiveinvestors.com

October 19, 2022 06:51 AM Eastern Daylight Time

Video

1 ... 166 167 168 169 170 ... 250